Tralokinumab, an anti-IL-13 antibody, is effective for atopic dermatitis (AD); however, its long-term (> 1 year) effectiveness specific to each anatomical site is unknown in real-world settings. To evaluate 72-week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate-to-severe AD treated with tralokinumab for 72 weeks. Eczema area and severity index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper limbs, and lower limbs). Tralokinumab consistently reduced EASI on all anatomical sites. The achievement rates of EASI 75 and 100 on each site gradually increased from Week 4 to Week 72, and those on lower limbs appeared higher compared to the other sites. The percent reductions of EASI throughout 72 weeks appeared slightly lower on head and neck compared to the other sites. Week 72 achievement rate of EASI 75 on head/neck, trunk, upper limbs, or lower limbs was 80.4%, 80%, 80.3%, or 86.7%, while that of EASI 100 was 37.3%, 25.0%, 27.4%, and 40.0%, respectively. Tralokinumab reduced EASI scores through 72 weeks across different anatomical sites in AD patients. The achievement rates of EASI 75 and 100 appeared slightly higher on lower limbs compared to the other sites.
Esophagectomy is associated with high morbidity. Prolonged surgical time, low body mass index, and hypoalbuminemia have been implicated as potential risk factors. However, their age-specific and nonlinear associations with postoperative outcomes remain unclear. This multicenter retrospective study included 338 patients who underwent elective esophagectomy for histologically confirmed esophageal cancer between 2018 and 2024. The primary outcome was a composite of severe complications within 30 days, including mortality, reoperation, renal replacement therapy, or mechanical ventilation. Multivariable logistic regression was used to evaluate risk factors, with age-stratified analysis (< 70 vs. ≥ 70 years) and restricted cubic spline modeling applied to assess nonlinear associations. The primary outcome occurred in 15.4
Real-world data are limited on 2 year effectiveness of tyrosine kinase 2 inhibitor deucravacitinib for psoriasis, especially that stratified by body mass index (BMI) or age. This study is aimed to evaluate 104 week effectiveness of deucravacitinib in patients with psoriasis, stratified by BMI (< 25 versus ≥ 25 kg/m2) or age (< 65 versus ≥ 65 years). We included 127 patients with moderate-to-severe psoriasis who received deucravacitinib 6 mg once daily. Psoriasis area and severity index (PASI) decreased throughout 104 weeks in whole patients. In between-group comparisons, mean percent reduction of PASI did not significantly differ at any time point in either BMI or age stratification. The amount of decreasing PASI and achievement rates of PASI 75, 90, and absolute PASI ≤ 2 through week 16 to 68 were slightly higher in BMI < 25 than in BMI ≥ 25, thereafter inverted order. The achievement rates of PASI 100 or absolute PASI ≤ 1 were higher in BMI < 25 throughout 104 weeks; week 104 PASI 100 or absolute PASI ≤ 1 rates were 16.7% or 54.2% in BMI < 25 while 0% or 40% in BMI ≥ 25, respectively. Percent reduction of PASI and achievement rates of PASI 75 and 90 were slightly higher in age ≥ 65 years than in age < 65 years by week 52, thereafter inverted order. Week 104 achievement rates of PASI 100 or absolute PASI ≤ 1 were 28.6% or 57.1% in age < 65 years while 0% or 46.7% in age ≥ 65 years, respectively. Deucravacitinib reduced PASI throughout 104 weeks in whole patients. Patients with BMI < 25 or age ≥ 65 years might show slightly higher response to deucravacitinib at early time points around 1 year compared to slightly higher response at later time points in those with BMI ≥ 25 or age < 65 years. Patients with BMI ≥ 25 or age ≥ 65 years might have difficulty in keeping PASI 100 through week 104.
